Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus

BACKGROUND: There are no clinically available prognostic models for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer treated with everolimus. We aimed to develop a tool to predict the progression-free survival (PFS) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Fangfang, Song, Chenge, Ma, Yuyu, Jiang, Kuikui, Xu, Fei, Bi, Xiwen, Huang, Jiajia, Hong, Ruoxi, Huang, Zhangzan, Lu, Qianyi, Yuan, Zhongyu, Wang, Shusen, Xia, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364432/
https://www.ncbi.nlm.nih.gov/pubmed/34408400
http://dx.doi.org/10.2147/DDDT.S314723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364432/
https://www.ncbi.nlm.nih.gov/pubmed/34408400
http://dx.doi.org/10.2147/DDDT.S314723

Ejemplares similares